Why Pharma products win or lose years before launch
In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Farrell Simon, Chief Commercial Officer at Trevi Therapeutics, to discuss what commercial leadership looks like long before launch, sharing lessons from a career that spans Procter & Gamble, Pfizer, and biotech.
Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice.
The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.
Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.
In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Farrell Simon, Chief Commercial Officer at Trevi Therapeutics, to discuss what commercial leadership looks like long before launch, sharing lessons from a career that spans Procter & Gamble, Pfizer, and biotech.
What You’ll Learn:
Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice.
The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.
Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.
Episode Resources:
Or join the Pharma Sessions Substack:
www.pharmasessions.substack.comPharma Sessions is handcrafted by our friends over at: fame.so
What You’ll Learn:
- How to start launch preparation in Phase 2
- The portfolio decision framework when scientific promise conflicts with commercial reality
- Why ‘failing fast’ in pharma means testing commercial execution
- How to keep distributed teams motivated across multi-year development cycles
- The culture and risk calculus for moving from large pharma to single-asset biotech
Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice.
The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.
Any reference to specific products, companies, regulatory pathways, or commercial strategies is provided for discussion purposes only and does not constitute endorsement or validation by the podcast, host, or sponsors.
Episode Resources:
- Farrell Simon on LinkedIn
- Trevi Therapeutics Website
- Jonathan Kaskey on LinkedIn
- XSUNT Corporation Website
Or join the Pharma Sessions Substack:
www.pharmasessions.substack.comPharma Sessions is handcrafted by our friends over at: fame.so
